Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Jazz Pharma Plc (JAZZ)

Jazz Pharma Plc (JAZZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,435,035
  • Shares Outstanding, K 56,573
  • Annual Sales, $ 1,891 M
  • Annual Income, $ 447,100 K
  • 60-Month Beta 1.13
  • Price/Sales 4.23
  • Price/Cash Flow 8.98
  • Price/Book 2.79

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 3.57
  • Number of Estimates 5
  • High Estimate 3.67
  • Low Estimate 3.36
  • Prior Year 3.27
  • Growth Rate Est. (year over year) +9.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
141.28 +3.11%
on 01/06/20
154.11 -5.47%
on 12/26/19
-8.06 (-5.24%)
since 12/24/19
3-Month
122.28 +19.13%
on 10/25/19
154.24 -5.56%
on 12/24/19
+22.18 (+17.96%)
since 10/24/19
52-Week
116.52 +25.02%
on 10/14/19
154.24 -5.56%
on 12/24/19
+19.94 (+15.86%)
since 01/24/19

Most Recent Stories

More News
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258

Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.

NVS : 93.91 (-1.06%)
AVDL : 6.86 (-8.90%)
JAZZ : 146.18 (-1.96%)
TEVA : 10.09 (-2.89%)
Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on January 21, 2020 seeking marketing approval for JZP-258,...

JAZZ : 146.18 (-1.96%)
PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period

PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announce that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended "HSR", with respect to the exclusive...

PHM : 43.97 (+0.27%)
JAZZ : 146.18 (-1.96%)
Jazz's (JAZZ) New Sleep Drug Sunosi Gets Approval in Europe

Jazz (JAZZ) receives approval for Sunosi as a treatment for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea patients in Europe.

NVS : 93.91 (-1.06%)
AVDL : 6.86 (-8.90%)
JAZZ : 146.18 (-1.96%)
TEVA : 10.09 (-2.89%)
Jazz Pharmaceuticals Receives EU Marketing Authorisation for Sunosi® (solriamfetol) for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Commission approved Sunosi® (solriamfetol) to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adults with...

JAZZ : 146.18 (-1.96%)
Plasminogen Activator Inhibitor 1, Pipeline Review, H2 2019 - Beam Therapeutics Inc, Jazz Pharmaceuticals Plc & MDI Therapeutics Inc - ResearchAndMarkets.com

The "Plasminogen Activator Inhibitor 1 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

JAZZ : 146.18 (-1.96%)
Jazz Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

JPM : 133.11 (-2.51%)
JAZZ : 146.18 (-1.96%)
JAZZ vs. ZTS: Which Stock Is the Better Value Option?

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

JAZZ : 146.18 (-1.96%)
ZTS : 136.54 (-1.30%)
Jazz Enrolls First Patient in Phase II/III Leukemia Study

Jazz (JAZZ) begins enrollment in the phase II/III study evaluating JZP-458 for treating pediatric and adult patients with acute lymphoblastic leukemia, hypersensitive to E. coli-derived asparaginases

INVA : 14.24 (-0.90%)
JAZZ : 146.18 (-1.96%)
ACRX : 1.77 (+3.51%)
GH : 80.30 (-1.50%)
Zacks.com featured highlights include: Lithia Motors, Marathon Petroleum, Meritage Homes, Jazz Pharmaceuticals and Barclays PLC

Zacks.com featured highlights include: Lithia Motors, Marathon Petroleum, Meritage Homes, Jazz Pharmaceuticals and Barclays PLC

LAD : 138.00 (-3.88%)
BCS : 9.01 (-0.11%)
MTH : 67.75 (-1.14%)
JAZZ : 146.18 (-1.96%)
MPC : 54.62 (-1.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade JAZZ with:

Business Summary

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and...

See More

Key Turning Points

2nd Resistance Point 152.06
1st Resistance Point 150.58
Last Price 146.24
1st Support Level 147.88
2nd Support Level 146.66

See More

52-Week High 154.24
Last Price 146.24
Fibonacci 61.8% 139.83
Fibonacci 50% 135.38
Fibonacci 38.2% 130.93
52-Week Low 116.52

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar